Significant Developments and Growth in Arecor Therapeutics' Operations Highlighted in Year-End Trading Update | Sarah Howell , CEO, Arecor Therapeutics PLC . 00:10:00
The year-end trading update from Arecor Therapeutics outlines significant advancements, including the European market launch of its Arestat technology-based product AT220, a 90% increase in gross revenue driven by successful partnerships and sales, finalization of patient enrollment for AT278 diabetes product with anticipated clinical data release, and notable growth in sales through Tetris Pharma, indicating substantial progress in its diabetes portfolio and specialty pharmaceutical business.
